The findings from KEYNOTE-158 and KEYNOTE-028 trials indicate that the effectiveness of pembrolizumab therapy appears to be unaffected by the expression of PDL1 in CCA cells [62]. The gene discussed is CD274; the disease is cholangiocarcinoma.